KR101995605B1 - 키나아제 활성의 조절 인자로서 새로운 이미다졸 아민 - Google Patents
키나아제 활성의 조절 인자로서 새로운 이미다졸 아민 Download PDFInfo
- Publication number
- KR101995605B1 KR101995605B1 KR1020147006807A KR20147006807A KR101995605B1 KR 101995605 B1 KR101995605 B1 KR 101995605B1 KR 1020147006807 A KR1020147006807 A KR 1020147006807A KR 20147006807 A KR20147006807 A KR 20147006807A KR 101995605 B1 KR101995605 B1 KR 101995605B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- fluoro
- imidazol
- trifluoromethyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161533601P | 2011-09-12 | 2011-09-12 | |
| US61/533,601 | 2011-09-12 | ||
| PCT/US2012/054900 WO2013040059A1 (en) | 2011-09-12 | 2012-09-12 | Novel imidazole amines as modulators of kinase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140063694A KR20140063694A (ko) | 2014-05-27 |
| KR101995605B1 true KR101995605B1 (ko) | 2019-07-02 |
Family
ID=46881179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147006807A Expired - Fee Related KR101995605B1 (ko) | 2011-09-12 | 2012-09-12 | 키나아제 활성의 조절 인자로서 새로운 이미다졸 아민 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9145392B2 (OSRAM) |
| EP (1) | EP2755965B1 (OSRAM) |
| JP (1) | JP5964974B2 (OSRAM) |
| KR (1) | KR101995605B1 (OSRAM) |
| CN (1) | CN104080782B (OSRAM) |
| AU (1) | AU2012308696B2 (OSRAM) |
| BR (1) | BR112014005554A2 (OSRAM) |
| CA (1) | CA2844830C (OSRAM) |
| DK (1) | DK2755965T3 (OSRAM) |
| EA (1) | EA025098B1 (OSRAM) |
| ES (1) | ES2644536T3 (OSRAM) |
| HR (1) | HRP20171554T1 (OSRAM) |
| HU (1) | HUE035019T2 (OSRAM) |
| IL (1) | IL231383A (OSRAM) |
| LT (1) | LT2755965T (OSRAM) |
| MX (1) | MX346095B (OSRAM) |
| NO (1) | NO2791461T3 (OSRAM) |
| PL (1) | PL2755965T3 (OSRAM) |
| PT (1) | PT2755965T (OSRAM) |
| RS (1) | RS56534B1 (OSRAM) |
| SG (2) | SG10201606301YA (OSRAM) |
| SI (1) | SI2755965T1 (OSRAM) |
| WO (1) | WO2013040059A1 (OSRAM) |
| ZA (1) | ZA201401013B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200093159A (ko) | 2019-01-28 | 2020-08-05 | 주식회사 링크모션 | 스마트 팜 모듈 구조물 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106946796B (zh) * | 2011-09-12 | 2020-05-08 | 默克专利有限公司 | 用作激酶活性调节剂的氨基嘧啶衍生物 |
| GEP201706623B (en) | 2012-10-16 | 2017-02-10 | Almirall Sa | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2014078634A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel imidazol-piperidinyl derivatives as modulators of kinase activity |
| SG10201900954SA (en) * | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
| CN105980375A (zh) * | 2014-02-11 | 2016-09-28 | 默克专利有限公司 | 用作激酶活性调节剂的嘧啶咪唑胺 |
| EP3205645B1 (en) | 2014-04-18 | 2019-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| HUE069128T2 (hu) | 2019-12-06 | 2025-02-28 | Vertex Pharma | Szubsztituált tetrahidrofurán vegyületek mint nátriumcsatornák modulátorai |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| CN117567435A (zh) * | 2022-01-30 | 2024-02-20 | 上海市第十人民医院 | 谷氨酰胺环化酶抑制剂及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140947A1 (en) | 2007-05-11 | 2008-11-20 | Eli Lilly And Company | P70 s6 kinase inhibitors |
| WO2010056563A1 (en) | 2008-11-11 | 2010-05-20 | Eli Lilly And Company | Akt and p70 s6 kinase inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7189729B2 (en) | 2003-09-30 | 2007-03-13 | Irm Llc | Methods and compositions as protein kinase inhibitors |
| WO2005039506A2 (en) | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| BRPI0416801A (pt) | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
| RU2006124421A (ru) | 2003-12-09 | 2008-01-20 | ПРАВИТЕЛЬСТВО СОЕДИНЕННЫХ ШТАТОВ АМЕРИКИ, ПРЕДСТАВЛЕННОЕ СЕКРЕТАРЕМ ДЕПАРТАМЕНТА ЗДРАВООХРАНЕНИЯ И СЛУЖБЫ ДЛЯ ЛЮДЕЙ, УС Национальный Институт здравоохранени , Ведомство по передаче технологий (US) | Способ подавления ответной иммунной реакции или лечения пролиферативного нарушения |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
| CA2595205A1 (en) * | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2006136821A1 (en) | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| CA2751886C (en) | 2009-02-11 | 2017-08-29 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| EP2598497B1 (en) | 2010-07-29 | 2019-03-06 | Merck Patent GmbH | Cyclic amine azaheterocyclic carboxamides |
| EP2643313B9 (en) | 2010-11-24 | 2017-02-22 | Merck Patent GmbH | Quinazoline carboxamide azetidines |
-
2012
- 2012-09-12 MX MX2014002832A patent/MX346095B/es active IP Right Grant
- 2012-09-12 CA CA2844830A patent/CA2844830C/en not_active Expired - Fee Related
- 2012-09-12 WO PCT/US2012/054900 patent/WO2013040059A1/en not_active Ceased
- 2012-09-12 US US14/237,075 patent/US9145392B2/en not_active Expired - Fee Related
- 2012-09-12 EP EP12761865.0A patent/EP2755965B1/en active Active
- 2012-09-12 HR HRP20171554TT patent/HRP20171554T1/hr unknown
- 2012-09-12 HU HUE12761865A patent/HUE035019T2/en unknown
- 2012-09-12 AU AU2012308696A patent/AU2012308696B2/en not_active Ceased
- 2012-09-12 BR BR112014005554A patent/BR112014005554A2/pt not_active IP Right Cessation
- 2012-09-12 JP JP2014529985A patent/JP5964974B2/ja not_active Expired - Fee Related
- 2012-09-12 RS RS20171075A patent/RS56534B1/sr unknown
- 2012-09-12 ES ES12761865.0T patent/ES2644536T3/es active Active
- 2012-09-12 SI SI201231104T patent/SI2755965T1/sl unknown
- 2012-09-12 DK DK12761865.0T patent/DK2755965T3/en active
- 2012-09-12 EA EA201400339A patent/EA025098B1/ru not_active IP Right Cessation
- 2012-09-12 CN CN201280054930.4A patent/CN104080782B/zh not_active Expired - Fee Related
- 2012-09-12 LT LTEP12761865.0T patent/LT2755965T/lt unknown
- 2012-09-12 SG SG10201606301YA patent/SG10201606301YA/en unknown
- 2012-09-12 PT PT127618650T patent/PT2755965T/pt unknown
- 2012-09-12 SG SG2014009278A patent/SG2014009278A/en unknown
- 2012-09-12 PL PL12761865T patent/PL2755965T3/pl unknown
- 2012-09-12 KR KR1020147006807A patent/KR101995605B1/ko not_active Expired - Fee Related
- 2012-12-11 NO NO12858293A patent/NO2791461T3/no unknown
-
2014
- 2014-02-10 ZA ZA2014/01013A patent/ZA201401013B/en unknown
- 2014-03-06 IL IL231383A patent/IL231383A/en active IP Right Grant
-
2015
- 2015-09-14 US US14/852,851 patent/US20160000785A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140947A1 (en) | 2007-05-11 | 2008-11-20 | Eli Lilly And Company | P70 s6 kinase inhibitors |
| WO2010056563A1 (en) | 2008-11-11 | 2010-05-20 | Eli Lilly And Company | Akt and p70 s6 kinase inhibitors |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200093159A (ko) | 2019-01-28 | 2020-08-05 | 주식회사 링크모션 | 스마트 팜 모듈 구조물 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101995605B1 (ko) | 키나아제 활성의 조절 인자로서 새로운 이미다졸 아민 | |
| AU2017245469B2 (en) | Aminopyrimidine derivatives for use as modulators of kinase activity | |
| EP2627650A2 (en) | N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1 | |
| AU2015217397B2 (en) | Pyrimidine imidazole amines as modulators of kinase activity | |
| HK1201825B (en) | Imidazole amines as modulators of kinase activity | |
| HK1228893A1 (en) | Pyrimidine imidazole amines as modulators of kinase activity | |
| HK1240220A1 (en) | Aminopyrimidine derivatives for use as modulators of kinase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20220627 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20220627 |